Literature DB >> 7540490

Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.

P S Eastman1, M Urdea, D Besemer, M Stempien, J Kolberg.   

Abstract

A mutation at codon 215 of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) gene results in decreased sensitivity to zidovudine (ZDV). In order to follow changes in codon 215 mutant (MUT) and wild-type (WT) populations in the plasma of patients during therapy, two polymerase chain reaction (PCR) procedures were investigated. The first was a nested, selective PCR, wherein a first round with viral-specific primers was followed by a second round with allele-specific primers. Although the procedure is relatively sensitive, some samples in the first round of PCR could not be amplified. In mixing experiments, mispriming of the MUT primer made relative determination of quantities subjective and difficult. Differential hybridization of PCR product with probes specific for codon 215 MUT or WT sequences was also investigated. A probe directed to a highly conserved region of the RT gene in the amplified PCR product was used to determine the total amount of PCR product analyzed. Differential hybridization was linear and reproducible over several logs of MUT:WT ratios, and determination of a 1:100 ratio of MUT:WT was readily achieved. When applied to longitudinal samples from three patients, dramatic changes in each population were readily apparent. These changes were evaluated with regard to viral load.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540490

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  5 in total

Review 1.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

2.  Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance.

Authors:  P S Eastman; E Boyer; L Mole; J Kolberg; M Urdea; M Holodniy
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

3.  Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.

Authors:  Shoukat H Qari; Richard Respess; Hillard Weinstock; Elise M Beltrami; Kurt Hertogs; Brendan A Larder; Christos J Petropoulos; Nicholas Hellmann; Walid Heneine
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

4.  Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.

Authors:  M B Vasudevachari; Y M Zhang; H Imamichi; T Imamichi; J Falloon; N P Salzman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D Kern; M Collins; T Fultz; J Detmer; S Hamren; J J Peterkin; P Sheridan; M Urdea; R White; T Yeghiazarian; J Todd
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.